Core Viewpoint - Baihua Pharmaceutical is undergoing a potential change in control as its major shareholders are planning to transfer shares, leading to a suspension of trading starting December 29, 2023 [1][4]. Group 1: Shareholder Changes - The major shareholders, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, are in the process of planning a share transfer that may result in a change of control of the company [1]. - The company will be suspended from trading for no more than two trading days starting December 29, 2023, with a closing price of 12.24 yuan per share and a market capitalization of 4.707 billion yuan as of December 26, 2023 [4]. - As of December 1, 2025, the shareholders confirmed the termination of their joint action agreement, which will automatically dissolve their unified action relationship [7]. Group 2: Shareholding Structure - Mi Zaiqi, Mi Enhua, and Yang Xiaoling collectively hold 20.68% of Baihua Pharmaceutical's shares, with individual holdings of 8.99%, 6.70%, and 4.99% respectively [9]. - Li Jiancheng, previously a joint action partner, no longer holds a controlling interest in the company, and his shares will not be included in the combined calculation [8]. Group 3: Financial Performance - Baihua Pharmaceutical has experienced significant fluctuations in its net profit since the change in control in 2019, with net profits recorded as 34.38 million yuan, -320 million yuan, 59.83 million yuan, -34.76 million yuan, 12.97 million yuan, and 41.48 million yuan from 2019 to 2024 [9]. - For the first three quarters of 2025, the company's net profit attributable to shareholders increased by 36.41% year-on-year, reaching 32.67 million yuan, attributed to improved project management and cost control [11]. - The total revenue for the current reporting period is 96.52 million yuan, reflecting a year-on-year increase of 2.32% [11].

Core Viewpoint - Baihua Pharmaceutical is planning a share transfer that may lead to a change in control of the company, with a trading suspension expected to last no more than two trading days starting December 29 [1]. Group 1: Shareholding Structure - The controlling shareholders, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, are in the process of transferring shares, which may alter the company's control [1]. - As of December 1, 2025, the agreement among Mi Zaiqi, Mi Enhua, Yang Xiaoling, and their former joint action partner Li Jiancheng has been terminated, resulting in a change in the calculation of shareholding percentages [3]. - Mi Zaiqi, Mi Enhua, and Yang Xiaoling collectively hold 20.68% of Baihua Pharmaceutical, with individual holdings of 8.99%, 6.70%, and 4.99% respectively [4]. Group 2: Financial Performance - Baihua Pharmaceutical has experienced significant fluctuations in net profit from 2019 to 2024, with figures of 34.38 million, -320 million, 59.83 million, -34.76 million, 12.97 million, and 41.48 million yuan respectively [4]. - In the first three quarters of 2025, the net profit attributable to shareholders increased by 36.41% year-on-year, driven by improved project management and cost control [6]. - The company's total revenue for the current reporting period is approximately 965.20 million yuan, reflecting a year-on-year increase of 2.32% [6].

百花医药（600721）(600721.SH)发布公告，公司于2025年12月26日收到公司控股股东、实际控制人米 在齐先生、米恩华先生、杨小玲女士的通知，米在齐先生、米恩华先生、杨小玲女士正在筹划公司股份 协议转让事宜，该事项可能导致公司控制权发生变更。公司股票将于2025年12月29日(星期一)开市起停 牌，预计停牌时间不超过2个交易日。 ...

智通财经APP讯，百花医药(600721.SH)发布公告，公司于2025年12月26日收到公司控股股东、实际控 制人米在齐先生、米恩华先生、杨小玲女士的通知，米在齐先生、米恩华先生、杨小玲女士正在筹划公 司股份协议转让事宜，该事项可能导致公司控制权发生变更。公司股票将于2025年12月29日(星期一)开 市起停牌，预计停牌时间不超过2个交易日。 ...

Group 1 - *ST Changyao received a warning for potential delisting due to three consecutive years of inflated revenue and profits, with a proposed fine of 10 million yuan for the company and 31 million yuan for 14 individuals involved [2] - Newquan Co. plans to issue H-shares and list on the Hong Kong Stock Exchange [3] - State Grid Yingda intends to sell 100% equity of Yingda Futures for 1.129 billion yuan [4] Group 2 - Baihua Pharmaceutical's controlling shareholders are planning a transfer of shares that may lead to a change in control, with trading suspension starting December 29 [5] - China Duty Free Group's subsidiary won a bid for the Beijing Capital International Airport duty-free project, with a guaranteed operating fee of 480 million yuan for the first year [6] - Yongding Co. clarified that it does not manufacture controlled nuclear fusion devices but provides materials for the magnetic coils, with minimal impact on its revenue [7] Group 3 - Zaiseng Technology reported no current orders for its high-silica fiber products, which have a negligible impact on overall revenue [8] - Hongxing Development announced the relocation and suspension of its subsidiary Dazuhongdie, with production equipment being transferred to another subsidiary [9] Group 4 - Meilixin received a supplier designation from a global commercial vehicle company, expecting total sales of approximately 640 million yuan over the next seven years [11] - Jianghe Group's subsidiary won a contract for a project worth about 112 million yuan, representing 0.5% of the company's projected revenue for 2024 [12] Group 5 - Xugong Machinery's controlling shareholder plans to increase its stake in the company by investing between 80 million and 160 million yuan [14] - Tengjing Technology's shareholder, Longyao Investment, intends to reduce its stake by up to 1.902% through block trading [15]

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-046 新疆百花村医药集团股份有限公司 关于筹划控制权变更事项的停牌公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因公司控股股东、实际控制人米在齐先生、米恩华先生、杨小玲女士正在筹 划公司股份协议转让事宜，该事项可能导致公司控制权发生变更，目前米在齐先 生、米恩华先生、杨小玲女士与交易对方正积极推进本次交易的相关工作，鉴于 该事项存在不确定性,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600721 | 百花医药 | A 股 | 停牌 | 2025/12/29 | | | | 新疆百花村医药集团股份有限公司（以下简称"百花医药"或"公司"）于 2025 年 12 月 26 日收到公司控股 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇12月26日｜百花医药（维权）(600721.SH)公告称，公司控股股东、实际控制人米在齐、米恩 华、杨小玲正在筹划公司股份协议转让事宜，可能导致公司控制权发生变更。为保证公平信息披露，维 护投资者利益，公司股票将于2025年12月29日开市起停牌，预计停牌时间不超过2个交易日。 ...

Market Overview - The medical services sector increased by 1.03% on December 25, with Baihua Medicine leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Gainers in Medical Services - Baihua Medicine (600721) closed at 11.56, up 6.54% with a trading volume of 396,400 shares and a transaction value of 449 million [1] - Zhaoyan New Drug (603127) closed at 37.38, up 4.24% with a trading volume of 254,500 shares and a transaction value of 266.56 million [1] - Aoyang Health (002172) closed at 4.18, up 3.98% with a trading volume of 330,500 shares and a transaction value of 137 million [1] Top Losers in Medical Services - Yinos (688710) closed at 44.60, down 1.87% with a trading volume of 16,000 shares and a transaction value of 71.19 million [2] - Baiao Saitou (688796) closed at 51.80, down 1.52% with a trading volume of 35,500 shares and a transaction value of 184 million [2] - Yangguang Nuohuo (688621) closed at 68.01, down 1.29% with a trading volume of 32,700 shares and a transaction value of 223 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 148 million from institutional investors and 126 million from retail investors, while retail investors saw a net inflow of 275 million [2] - Zhaoyan New Drug had a net inflow of 164 million from institutional investors, while Baihua Medicine saw a net inflow of 45.83 million [3] - The overall capital flow indicates a mixed sentiment among different investor categories within the medical services sector [3]

特此公告。 证券代码：600721 证券简称：百花医药 公告编号：2025-045 新疆百花村医药集团股份有限公司 关于聘任公司轮值总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 新疆百花村医药集团股份有限公司（以下简称"公司"）于2025年12月19日分别召开第九届董事会提名委 员会2025年第二次会议、第九届董事会第九次会议，审议通过了《关于聘任公司2026年度轮值总经理的 议案》，根据《公司章程》《公司轮值总经理管理制度》等有关规定，经公司董事长提名，并经公司董 事会提名委员会审议通过，董事会同意聘任黄辉先生为公司2026年度轮值总经理，任期一年。 黄辉：男，汉族，1984年出生，南京大学化学化工学院有机化学专业硕士研究生毕业。曾任常熟华益化 工有限公司埃索托普分公司小分子药物研发负责人，南京华威医药科技集团有限公司化学总监、技术总 监、副总经理、总经理，现任公司董事、2026年度轮值总经理、南京华威医药科技集团有限公司董事 长、江苏礼华生物技术有限公司副董事长。 曾领导医药研发团队完成超过80项新药仿制药 ...

Group 1 - The property management sector saw an increase of 2.88%, ranking 9th among concept sectors, with 168 stocks rising, including Debi Group which hit a 20% limit up [1] - Notable gainers in the property management sector included Guangyu Group, Sanxiang Impression, and Sanmu Group, all reaching their daily limit up [1] - The top gainers in the market included Central Mall, Baihua Pharmaceutical, and Huitong Energy, with increases of 8.97%, 7.80%, and 7.49% respectively [1] Group 2 - The property management concept attracted a net inflow of 1.265 billion yuan, with 99 stocks receiving net inflows, and 5 stocks exceeding 100 million yuan in net inflow [2] - Dongbai Group led the net inflow with 310 million yuan, followed by Debi Group, Hualian Holdings, and Hongmian Co., which received net inflows of 166 million yuan, 141 million yuan, and 126 million yuan respectively [2] - The net inflow ratios for Tianchen Co., Hongmian Co., and Debi Group were 43.74%, 39.25%, and 23.56% respectively, indicating strong investor interest [3] Group 3 - The property management sector's performance was highlighted by significant stock movements, with Debi Group showing a daily increase of 19.99% and a turnover rate of 21.46% [3] - Other notable performers included Hualian Holdings and Hongmian Co., with daily increases of 10.02% and 10.03% respectively [4] - The overall market sentiment in the property management sector appears positive, as evidenced by the strong performance of multiple stocks within the sector [1][2]